Efficacy

Cyramza (Ramucirumab) Efficacy in Lung Cancer

Cyramza (ramucirumab) is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that has been approved for use in the treatment of non-small cell lung cancer (NSCLC) in combination with docetaxel, after prior platinum-based chemotherapy has failed. Clinical trials have demonstrated that Cyramza, when added to docetaxel, can lead to an improvement in overall survival compared to docetaxel alone in patients with advanced or metastatic NSCLC. The REVEL trial, a pivotal phase III study, showed that patients receiving Cyramza plus docetaxel had a median overall survival of 10.5 months compared to 9.1 months in the placebo plus docetaxel group, which was statistically significant.

Furthermore, Cyramza has shown efficacy in increasing progression-free survival (PFS) and improving the objective response rate (ORR) in the same patient population. The REVEL trial reported a median PFS of 4.5 months with Cyramza plus docetaxel versus 3.0 months with placebo plus docetaxel. The ORR was also higher in the Cyramza group at 23% compared to 14% in the placebo group. These results support the use of Cyramza in combination with docetaxel for the second-line treatment of patients with NSCLC.

Retsevmo (Selpercatinib) Efficacy in Lung Cancer

Retsevmo (selpercatinib) is a selective RET kinase inhibitor approved for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). Selpercatinib has shown significant efficacy in patients with RET fusion-positive NSCLC who are treatment-naive or have been previously treated with platinum chemotherapy. The LIBRETTO-001 trial, a multi-cohort, open-label, phase 1/2 study, demonstrated a robust response to selpercatinib in this patient population. The trial reported an ORR of 64% in previously treated patients and 85% in treatment-naive patients, indicating a high level of activity against RET-driven tumors.

In addition to high response rates, selpercatinib has also been associated with a durable response. The LIBRETTO-001 trial showed that the median duration of response (DoR) was not reached at the time of data cut-off, suggesting that the responses are long-lasting. Moreover, selpercatinib was effective in controlling brain metastases, which is a common and challenging complication in lung cancer. The intracranial ORR for patients with measurable brain metastases was 91%, highlighting the potential of selpercatinib to manage central nervous system involvement in RET fusion-positive NSCLC.